Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly
MYGN [NASD]
Myriad Genetics Inc.
Services | Research Services | USA
financial highlights | statements
Index- P/E20.02 EPS (ttm)1.57 Insider Own0.22% Shs Outstand79.65M Perf Week-4.56%
Market Cap2.50B Forward P/E16.99 EPS next Y1.85 Insider Trans-10.24% Shs Float79.20M Perf Month13.51%
Income132.21M PEG1.40 EPS next Q0.44 Inst Own95.56% Short Float5.41% Perf Quarter25.77%
Sales572.01M P/S4.38 EPS this Y18.11% Inst Trans-2.03% Short Ratio3.64 Perf Half Y4.63%
Book/sh8.33 P/B3.77 EPS next Y10.78% ROA18.51% Target Price32.83 Perf Year21.92%
Cash/sh4.22 P/C7.45 EPS next 5Y14.25% ROE20.07% 52W Range22.02 - 34.70 Perf YTD15.34%
Dividend- P/FCF17.66 EPS past 5Y19.97% ROI19.77% 52W High-9.42% Beta0.35
Dividend %- Quick Ratio8.22 Sales past 5Y27.84% Gross Margin86.98% 52W Low42.73% ATR1.01
Employees1169 Current Ratio8.35 Sales Q/Q20.57% Oper. Margin36.60% RSI (14)57.68 Volatility2.94% 3.07%
OptionableYes Debt/Eq0.00 EPS Q/Q34.20% Profit Margin23.11% Rel Volume0.94 Prev Close32.19
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout0.00% Avg Volume1.18M Price31.43
Recom2.10 SMA202.45% SMA5012.89% SMA20016.03% Volume1,104,565 Change-2.36%
10-May-13Reiterated Mizuho Buy $34 → $36
08-May-13Upgrade Mizuho Neutral → Buy $27 → $34
03-Apr-13Reiterated Mizuho Neutral $30 → $27
05-Feb-13Downgrade Ladenburg Thalmann Buy → Neutral
03-Dec-12Downgrade Mizuho Buy → Neutral $31 → $30
06-Nov-12Reiterated Mizuho Buy $29 → $31
01-Oct-12Initiated WallachBeth Buy $31
02-May-12Reiterated Mizuho Buy $27 → $29
02-Nov-11Upgrade Ticonderoga Neutral → Buy $25
12-Sep-11Upgrade Auriga Hold → Buy $21 → $24
15-Jun-11Downgrade Auriga Buy → Hold $27 → $25
17-Mar-11Initiated Oppenheimer Perform $22
17-Dec-10Reiterated Auriga U.S.A Buy $23 → $27
03-Nov-10Reiterated UBS Neutral $16 → $20
13-Oct-10Upgrade RBC Capital Mkts Sector Perform → Outperform $23
16-Jun-10Initiated Gleacher & Company Sell $15
13-May-10Upgrade Auriga U.S.A Sell → Buy $19 → $23
29-Mar-10Downgrade Mehta Partners Outperform → Market Perform $32 → $29
05-Mar-10Initiated Auriga U.S.A Sell $19
21-Jan-10Initiated Jefferies & Co Hold $24
23-May-13 10:10AM  Covidien's ENB Adopted by ACCP Zacks
22-May-13 10:00AM  6 Ways You Can Profit From Molecular Diagnostics at Seeking Alpha
08:09AM  The Curious Case Of Human Gene Patents at Forbes
21-May-13 01:52PM  Splicing & Dicing Myriad Genetics Amidst the Angelina Jolie Disclosure at Motley Fool
01:50PM  QIAGEN Downgraded to Strong Sell Zacks
12:07PM  Charting a persistent May uptrend at MarketWatch
09:30AM  FDA Nod for COV's Advanced Nellcor Zacks
20-May-13 09:50AM  U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer at Bloomberg
19-May-13 01:00PM  The Implications of Monsanto's Supreme Court Win at Motley Fool
09:38AM  Myriad Genetics: Disruptive Products For Cancer Diagnostics at Seeking Alpha
17-May-13 01:20PM  CE Mark for STJ's ILUMIEN OPTIS Zacks
12:20PM  Stryker Reiterated at Neutral Zacks
16-May-13 03:30PM  SGEN's Adcetris under FDA Review Zacks
08:40AM  Covidien Prices Senior Notes Zacks
15-May-13 07:00PM  The Stock That May Have Saved Angelina Jolie's Life Could Get Another Boost StreetAuthority Network
07:00PM  The Stock That May Have Saved Angelina Jolie's Life Could Get Another Boost
06:40PM  Angelina Jolie's Selfless Act Heightens Breast Cancer Awareness at Motley Fool
06:27PM  Genomic Health's New Prostate Test May Extend The Stock's Upward Climb at Seeking Alpha
03:18PM  Company That Sells Angelina Jolies Blood Test YCharts
02:30PM  Much Awaited Test Launch by Genomic Zacks
02:00PM  Myriad Soars Higher on Celeb Clout Zacks
01:33PM  The Angelina Jolie Connection: The Debate Over Patenting Human Genes at Minyanville
01:04PM  MYRIAD GENETICS INC Financials EDGAR Online Financials
09:18AM  Myriad Genetics: Strong Results Ahead Of Supreme Court Decision at Seeking Alpha
05:33AM  Stocks to Watch: Cisco, BlackBerry, Macy's TheStreet
03:14AM  Myriad trade expects sharp move optionMONSTER
14-May-13 06:55PM  Angelina Jolie star power extends to stock at MarketWatch
06:55PM  Angelina Jolie star power extends to stock at MarketWatch
05:39PM  Myriad Genetics shares rise to three-year highs AP
05:27PM  Roche Wins FDA Approval for Test to Target Lung Cancer at Bloomberg
05:18PM  At least one company benefits from Angelina Jolie cancer revelation at MarketWatch
05:13PM  Angelina Jolie star power extends to stock at MarketWatch
05:13PM  Angelina Jolie star power extends to stock at MarketWatch
05:12PM  Angelina Jolie star power extends to stock at MarketWatch
03:50PM  Angelina Jolie Reveals Double Mastectomy - Should You Get Genetic Testing? at Forbes
03:46PM  Angelina Jolie gives star power to stock at MarketWatch
02:28PM  Jolie's mastectomy highlights genetic testing company at CNNMoney.com
01:53PM  Jolie's Decision Boosts BRCA Test-Maker Myriad at CNBC
12:07PM  Stocks Add To Gains; LinkedIn Retakes 50-Day Line at Investor's Business Daily
12:00PM  Myriad Genetics climbs after Jolie reveals genetic testing at theflyonthewall.com
11:05AM  Myriad Genetics Shares Climb After Angelina Jolie Has Mastectomy The Exchange
07:05AM  Myriad Genetics to Present at the Bank of America Merrill Lynch Health Care Conference GlobeNewswire
13-May-13 06:06PM  Do These Top Stock Picks Have More Room to Grow? at Motley Fool
01:50PM  Genomic Gains Coverage for DCIS Zacks
01:38PM  Sony Options Active As Shares Hit Fresh 52-Week High at Seeking Alpha
11:55AM  Bulls show faith in Myriad Genetics optionMONSTER
09:01AM  Haverty Furniture Part-Owner Sells 25K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
08:50AM  Earnings Beat for PETS, Margins Up Zacks
07:08AM  Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert at Seeking Alpha
12-May-13 02:58PM  These 5 Stocks Saw Trading Price Swings This Past Week Post Earnings at Wall St. Cheat Sheet
11-May-13 08:39PM  Myriad Genetics' CEO Hosts Annual Day (Transcript) at Seeking Alpha
10:07AM  The Best- And Worst-Performing Biotech Stocks, May 3 To May 10 at Forbes
10-May-13 12:44PM  Myriad Stock Hits New 52-Week High (MYGN) at TheStreet +8.60%
12:37PM  Analysts: Apple Margin Concerns are Overblown and 2 Other Research Notes to Read at Wall St. Cheat Sheet
09-May-13 10:02AM  Companies Fighting Against Prostate Cancer at Seeking Alpha
08-May-13 04:45PM  MYGN Earnings Easily Beat, Guidance Up Zacks +8.23%
04:10PM  Genetic Test Helps Identify Aggressive Prostate Cancer at Bloomberg
03:31PM  Myriad Rises On Unusually High Volume (MYGN) at TheStreet
01:03PM  Today's Top Performers In Diversified Services at TheStreet
12:21PM  Myriad Genetics rises on 3Q and stronger outlook AP
08:49AM  Genetic Tests Help Identify Aggressive Prostate Cancer at Bloomberg
02:31AM  MYRIAD GENETICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
12:27AM  Gene test may help guide prostate cancer treatment AP
12:13AM  Gene test may help guide prostate cancer treatment AP
12:01AM  New Test Improves Assessment of Prostate Cancer Risk, Study Says at New York Times
12:01AM  New Test Improves Assessment of Prostate Cancer Risk, Study Says at New York Times
07-May-13 10:17PM  Myriad Genetics upgraded by Mizuho Briefing.com
07:30PM  Myriad Genetics Management Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha
05:22PM  Myriad Genetics Earnings: Everything You Must Know Now at Wall St. Cheat Sheet
05:08PM  BRIEF-Myriad Genetics up 3.3 percent in extended trade at Reuters
04:24PM  InPlay: Myriad Genetics beats by $0.07, beats on revs; guides FY13 EPS above consensus, revs above consensus Briefing.com
04:05PM  Myriad Genetics Reports Third Quarter Fiscal Year 2013 Results GlobeNewswire
09:15AM  MYRIAD GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib EDGAR Online
07:07AM  Q3 2013 Myriad Genetics Earnings Release - After Market Close CCBN
03-May-13 03:16PM  Atossa Genetics' Portfolio Can Detect Breast Cancer, But Can These Products Eradicate It? at Seeking Alpha
02-May-13 04:05PM  Myriad Genetics Announces 2013 Analyst and Investor Day GlobeNewswire
11:48AM  [$$] New Prostate-Cancer Tests Bring New Hopes at Barrons.com
07:07AM  InPlay: Myriad Genetics to present new molecular data for patients with prostate cancer at the American Urological Association 2013 Annual Meeting; PROLARIS signature consistently demonstrated additional prognostic utility beyond what is av Briefing.com
07:00AM  Myriad to Present New Molecular Data for Patients With Prostate Cancer at the American Urological Association 2013 Annual Meeting GlobeNewswire
01-May-13 08:50AM  Qiagen Misses Earnings, Guides Low Zacks
24-Apr-13 07:49AM  What If They Treated Gene Patents Like Nautical Charts? at Forbes
23-Apr-13 04:12PM  [$$] Blood Test May Help Diagnose Autism at The Wall Street Journal
01:20PM  [$$] Blood Test May Help Diagnose Autism at The Wall Street Journal
10:41AM  [$$] Blood Test May Help Diagnose Autism at The Wall Street Journal
22-Apr-13 04:55AM  Myriad Genetics: Growth Stock, Hot Sector, Solid Industry at Seeking Alpha
21-Apr-13 03:02PM  The Other Landmark Supreme Court Case at Motley Fool
18-Apr-13 04:05PM  Myriad Genetics to Announce Third Fiscal Quarter 2013 Results on Tuesday, May 7, 2013 GlobeNewswire
02:30PM  Myriad Downgraded to Neutral Zacks
11:00AM  Is This Ticking Time Bomb A Cornerstone of Your Portfolio? at Motley Fool
17-Apr-13 04:05PM  Myriad Adopts RainDance's Thunderstorm Platform for Next-Generation Sequencing Based Hereditary Cancer Panel GlobeNewswire
16-Apr-13 07:38PM  Calvert Crary, Wall Street Eye on Corporate Lawsuits, Dies at 69 at Bloomberg
12:09PM  Charting the market crosscurrents at MarketWatch
12:09PM  Charting the market crosscurrents at MarketWatch
12:00AM  Wachtell, WilmerHale, Cravath, Skadden: Business of Law at Bloomberg
12:00AM  Patenting Genes, Trolls, Domains: Intellectual Property at Bloomberg
15-Apr-13 06:17PM  Nasdaq stocks posting largest percentage increases AP
05:56PM  Supreme Court hearing on Myriad gene case encourages investors at MarketWatch
05:02PM  Myriad Genetics (MYGN) Shares Cross Above 200 DMA at TheStreet
04:40PM  Patenting genes: Justices tackle big health issue AP
02:41PM  3 Stocks Spiking on Big Volume at TheStreet
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Its molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual's risk for developing disease later in life; determine a patient's likelihood of responding to a particular drug; assess a patient's risk of disease progression and disease recurrence; and measure a patient's exposure to drug therapy to ensure optimal dosing and reduced drug toxicity. The company offers various molecular diagnostic tests that include BRACAnalysis predictive medicine test for hereditary breast and ovarian cancer; COLARIS medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; and MELARIS medicine test for hereditary melanoma. It also provides OnDose, a personalized medicine test that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. In addition, the company, through its subsidiary, Myriad RBM, Inc., offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Capone Mark ChristopherPresident, MGLMay 16Option Exercise17.6879,9991,414,183108,268May 17 05:21 PM
Capone Mark ChristopherPresident, MGLMay 16Sale33.2379,9992,658,51148,268May 17 05:21 PM
MELDRUM PETER DPresident & C.E.O.May 14Option Exercise7.8215,000117,300100,312May 14 05:24 PM
MELDRUM PETER DPresident & C.E.O.May 14Sale34.0015,000510,00085,312May 14 05:24 PM
MELDRUM PETER DPresident & C.E.O.May 10Option Exercise7.8272,022563,212110,312May 10 05:10 PM
MARSH RICHARD ME.V.P., General CounselMay 10Option Exercise12.1748,192586,49768,707May 10 05:08 PM
DREISMANN HEINRICHDirectorMay 10Option Exercise18.0530,000541,50030,000May 10 05:06 PM
DREISMANN HEINRICHDirectorMay 10Sale31.1630,000934,8270May 10 05:06 PM
MARSH RICHARD ME.V.P., General CounselMay 10Sale33.0048,1921,590,56320,515May 10 05:08 PM
MELDRUM PETER DPresident & C.E.O.May 10Sale32.0472,0222,307,68285,312May 10 05:10 PM
MELDRUM PETER DPresident & C.E.O.May 08Option Exercise7.823,93830,79589,250May 10 05:10 PM
MELDRUM PETER DPresident & C.E.O.May 08Sale31.003,938122,07885,312May 10 05:10 PM
HENDERSON JOHN TDirectorDec 10Option Exercise6.7040,000267,90022,746Dec 11 05:13 PM
HENDERSON JOHN TDirectorDec 10Sale27.6540,0001,106,1934,000Dec 11 05:13 PM
LANCHBURY JERRY SChief Scientific OfficerDec 03Option Exercise8.6320,000172,60037,735Dec 04 04:39 PM
LANCHBURY JERRY SChief Scientific OfficerDec 03Sale27.1820,000543,68017,735Dec 04 04:39 PM
LANGER DENNISDirectorNov 30Option Exercise19.9345,000896,70030,000Dec 03 04:57 PM
LANGER DENNISDirectorNov 30Sale29.9145,0001,345,9700Dec 03 04:57 PM
Harrison Robert GardnerChief Information OfficerNov 30Sale29.953,480104,2232,307Dec 04 04:38 PM
LANGER DENNISDirectorNov 29Option Exercise14.1225,000352,90015,000Dec 03 04:57 PM
LANGER DENNISDirectorNov 29Sale29.8225,000745,5010Dec 03 04:57 PM
Capone Mark ChristopherPresident, MGLNov 21Option Exercise16.533145,19048,582Nov 21 12:44 PM
Capone Mark ChristopherPresident, MGLNov 21Sale30.033149,43148,268Nov 21 12:44 PM
Capone Mark ChristopherPresident, MGLNov 20Option Exercise16.0435,010561,41277,954Nov 21 12:44 PM
Capone Mark ChristopherPresident, MGLNov 20Sale30.4135,0101,064,65448,268Nov 21 12:44 PM
LANCHBURY JERRY SChief Scientific OfficerNov 19Option Exercise10.6649,004522,46537,735Nov 21 12:46 PM
MELDRUM PETER DPresident & C.E.O.Nov 19Option Exercise5.8920,000117,800104,225Nov 21 12:48 PM
MELDRUM PETER DPresident & C.E.O.Nov 19Sale30.5920,000611,87484,225Nov 21 12:48 PM
LANCHBURY JERRY SChief Scientific OfficerNov 19Sale30.5949,0041,499,17917,735Nov 21 12:46 PM
MELDRUM PETER DPresident & C.E.O.Nov 12Option Exercise5.8925,000147,250109,225Nov 13 05:09 PM
Capone Mark ChristopherPresident, MGLNov 12Option Exercise13.2862,176825,697110,444Nov 13 05:12 PM
Capone Mark ChristopherPresident, MGLNov 12Sale29.9162,1761,859,79648,268Nov 13 05:12 PM
MELDRUM PETER DPresident & C.E.O.Nov 12Sale29.9125,000747,83884,225Nov 13 05:09 PM
MELDRUM PETER DPresident & C.E.O.Nov 09Option Exercise5.8925,000147,250109,225Nov 13 05:09 PM
MELDRUM PETER DPresident & C.E.O.Nov 09Sale29.7125,000742,79384,225Nov 13 05:09 PM
MELDRUM PETER DPresident & C.E.O.Nov 08Option Exercise6.0018,218109,308102,443Nov 08 04:24 PM
MELDRUM PETER DPresident & C.E.O.Nov 08Sale29.6118,218539,36484,225Nov 08 04:24 PM
MARSH RICHARD ME.V.P., General CounselNov 06Option Exercise8.1762,900514,13665,833Nov 08 04:15 PM
LANCHBURY JERRY SChief Scientific OfficerNov 06Option Exercise7.8229,882233,67734,517Nov 08 04:19 PM
Capone Mark ChristopherPresident, MGLNov 06Option Exercise12.1727,000328,59069,460Nov 08 04:08 PM
Harrison Robert GardnerChief Information OfficerNov 06Option Exercise13.9138,446534,65327,333Nov 08 04:12 PM
Harrison Robert GardnerChief Information OfficerNov 06Sale30.0538,4461,155,1876,657Nov 08 04:12 PM
Capone Mark ChristopherPresident, MGLNov 06Sale28.7527,000776,25048,268Nov 08 04:08 PM
LANCHBURY JERRY SChief Scientific OfficerNov 06Sale30.4229,882909,07317,735Nov 08 04:19 PM
MARSH RICHARD ME.V.P., General CounselNov 06Sale29.0562,9001,827,00024,029Nov 08 04:15 PM
MARSH RICHARD ME.V.P., General CounselOct 23Option Exercise12.7011,132141,38624,029Oct 24 05:06 PM
LANCHBURY JERRY SChief Scientific OfficerOct 04Option Exercise7.823,90030,49821,635Oct 09 10:40 AM
LANCHBURY JERRY SChief Scientific OfficerOct 04Sale28.503,900111,15017,735Oct 09 10:40 AM
LANCHBURY JERRY SChief Scientific OfficerOct 03Option Exercise7.823,00023,46020,735Oct 04 04:21 PM
LANCHBURY JERRY SChief Scientific OfficerOct 03Sale28.503,00085,50017,735Oct 04 04:21 PM
Evans James SChief Financial OfficerOct 02Option Exercise5.8935,000206,15077,401Oct 03 05:09 PM
Evans James SChief Financial OfficerOct 02Sale28.0635,000982,19546,771Oct 03 05:09 PM
Evans James SChief Financial OfficerSep 28Option Exercise4.4426,250116,55073,021Sep 28 05:42 PM
Evans James SChief Financial OfficerSep 28Sale26.9926,250708,39646,771Sep 28 05:42 PM
LANCHBURY JERRY SChief Scientific OfficerSep 17Sale28.005,000140,00017,735Sep 19 04:05 PM
MELDRUM PETER DPresident & C.E.O.Sep 14Option Exercise6.0020,000120,000172,225Sep 14 04:22 PM
MELDRUM PETER DPresident & C.E.O.Sep 14Sale27.6020,000552,008152,225Sep 14 04:22 PM
Evans James SChief Financial OfficerSep 13Option Exercise3.805,49420,87752,265Sep 14 04:19 PM
Evans James SChief Financial OfficerSep 13Sale27.105,494148,88746,771Sep 14 04:19 PM
Evans James SChief Financial OfficerSep 12Option Exercise3.8010,09138,34656,862Sep 12 04:51 PM
Evans James SChief Financial OfficerSep 12Sale27.0810,091273,25746,771Sep 12 04:51 PM
Evans James SChief Financial OfficerSep 11Option Exercise3.805,31620,20152,087Sep 12 04:51 PM
MARSH RICHARD ME.V.P., General CounselSep 11Option Exercise7.828,98170,23124,830Sep 12 04:52 PM
MELDRUM PETER DPresident & C.E.O.Sep 11Option Exercise6.0020,000119,997172,223Sep 12 04:55 PM
MELDRUM PETER DPresident & C.E.O.Sep 11Sale26.9220,000538,492152,225Sep 12 04:55 PM
MARSH RICHARD ME.V.P., General CounselSep 11Sale27.008,981242,50115,849Sep 12 04:52 PM
Evans James SChief Financial OfficerSep 11Sale26.975,316143,37846,771Sep 12 04:51 PM
Evans James SChief Financial OfficerSep 10Option Exercise3.809,09934,57654,273Sep 12 04:51 PM
MARSH RICHARD ME.V.P., General CounselSep 10Option Exercise7.8210,31980,69526,168Sep 12 04:52 PM
Capone Mark ChristopherPresident, MGLSep 10Option Exercise8.9519,805177,21363,372Sep 12 04:54 PM
Capone Mark ChristopherPresident, MGLSep 10Sale27.0019,805534,73549,268Sep 12 04:54 PM
MARSH RICHARD ME.V.P., General CounselSep 10Sale27.0010,319278,61315,849Sep 12 04:52 PM
Evans James SChief Financial OfficerSep 10Sale26.959,099245,22046,771Sep 12 04:51 PM
GILBERT WALTER PHDDirectorAug 21Option Exercise16.4617,198283,07917,198Aug 21 05:55 PM
GILBERT WALTER PHDDirectorAug 21Sale26.1017,198448,8200Aug 21 05:55 PM
GILBERT WALTER PHDDirectorAug 20Option Exercise11.6542,802498,72120,000Aug 21 05:55 PM
GILBERT WALTER PHDDirectorAug 20Sale25.9442,8021,110,3870Aug 21 05:55 PM
MELDRUM PETER DPresident & C.E.O.Aug 01Option Exercise13.285,32470,703186,225Aug 03 04:28 PM
Evans James SChief Financial OfficerJul 18Option Exercise8.6815,400133,67261,827Jul 18 04:21 PM
Evans James SChief Financial OfficerJul 18Sale26.0115,400400,60546,771Jul 18 04:21 PM
MELDRUM PETER DPresident & C.E.O.Jul 13Option Exercise8.681,47812,829182,379Jul 13 04:50 PM
MELDRUM PETER DPresident & C.E.O.Jul 13Sale25.901,47838,280180,901Jul 13 04:50 PM
MELDRUM PETER DPresident & C.E.O.Jul 10Option Exercise8.688,52273,971189,423Jul 11 04:06 PM
MELDRUM PETER DPresident & C.E.O.Jul 10Sale25.918,522220,799180,901Jul 11 04:06 PM
MELDRUM PETER DPresident & C.E.O.Jul 09Option Exercise8.6820,000173,600200,901Jul 11 04:06 PM
MELDRUM PETER DPresident & C.E.O.Jul 09Sale25.6420,000512,858180,901Jul 11 04:06 PM
open in yahoo | open in reuters | open in google